Novo Says High-Dose Wegovy Can Cause 28% Weight Loss

Why It Matters

The data demonstrate that a higher‑dose semaglutide can match or exceed rival efficacy, giving Novo a tool to recapture obesity market share and influence payer and prescribing decisions.

Key Takeaways

• Early responders lost nearly 28% body weight in 72 weeks.
• Average weight loss across trial was 21% with 7.2 mg dose.
• 27% of participants qualified as early responders after 24 weeks.
• Fat loss accounted for 84% of total weight reduction.
• Lean muscle loss limited to about 10% in MRI sub‑study.

Pulse Analysis

The obesity therapeutics market has accelerated dramatically since GLP‑1 agonists entered mainstream prescribing. Novo Nordisk’s flagship product, Wegovy (semaglutide), originally launched at a 2.4 mg dose, now offers a triple‑strength 7.2 mg formulation that received regulatory clearance in the United Kingdom, United States, European Union and Brazil earlier this year. By delivering a higher weekly exposure, the new dose aims to deepen weight‑loss outcomes for patients who struggle to meet the 15 % threshold that insurers often require. Its introduction coincides with intensifying competition from Eli Lilly’s tirzepatide‑based Zepbound, which has already demonstrated superior efficacy in head‑to‑head studies.

Data presented at the European Congress on Obesity reveal that the STEP UP trial, enrolling 1,400 adults with obesity, produced an average 21 % reduction in body weight after 72 weeks of treatment with Wegovy 7.2 mg. Notably, 27 % of participants entered an ‘early‑responder’ cohort, shedding almost 28 % of their baseline weight within the first six months. Advanced imaging of a 55‑patient subset showed that 84 % of the loss was adipose tissue, while lean muscle declined only about 10 %, alleviating concerns about functional deterioration. Abdominal fat fell 30 %, a clinically meaningful shift for cardiometabolic risk.

The robust efficacy signals give Novo a strategic lever to stem the erosion of its obesity market share. Higher‑dose Wegovy can now claim comparable, if not superior, weight‑loss percentages to Zepbound, allowing the company to “level the playing field” from an efficacy standpoint, as its executives noted. If early‑responder adoption accelerates, payors may favor the triple‑strength option for patients needing rapid, durable results, potentially boosting Novo’s revenue trajectory and shaping future GLP‑1 development pipelines toward dose‑escalation strategies.